Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of the International Consensus Classification of myelodysplastic syndromes.

British journal of haematology - 1 May 2023

Zhang Yudi, Wu Junying, Xu Zefeng, Qin Tiejun, Qu Shiqiang, Pan Lijuan, Wang Huijun, Sun Qi, Li Chengwen, Jia Yujiao, Cai Wenyu, Yan Xin, Gong Jingye, Gao Qingyan, Li Bing, Gale Robert Peter, Xiao Zhijian

Abstract excerpt

The impact of the 2022 International Consensus Classification (ICC) of myelodysplastic syndromes (MDS) needs study. We analysed data from 989 MDS subjects classified using the 2016 World Health Organization (WHO) criteria to determine the impact of the new proposal. Our analyses suggested the ICC criteria of MDS-SF3B1 identifies a more homogenous disease entity than the WHO 2016 criteria of myelodysplastic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Consensus
Share to International Classification of Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myelodysplastic Syndromes

Share to World Health Organization

Source

Identifiers

PMID: 36575970
DOI: 10.1111/bjh.18628

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of the International Consensus Classification of myelodysplastic syndromes.PMID 36575970Read ↗

Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.Semantic proximity Read ↗

Comparison of the 2022 World Health Organization Classification and International Consensus Classification in Myelodysplastic Syndromes/NeoplasmsSemantic proximity Read ↗

Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms.Semantic proximity Read ↗

Reclassification of Myelodysplastic Neoplasms According to the 2022 World Health Organization Classification and the 2022 International Consensus Classification Using Open-Source Data: Focus on SF3B1- and TP53-mutated Myelodysplastic Neoplasms.Semantic proximity Read ↗

Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.Semantic proximity Read ↗

Diagnosis and classification of myelodysplastic syndromesSemantic proximity Read ↗

Myelodysplastic syndromes, thy name is heterogeneity.Semantic proximity Read ↗

The International Consensus Classification of myelodysplastic syndromes and related entities.Semantic proximity Read ↗

Myelodysplastic Syndrome Updated.Semantic proximity Read ↗

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.Semantic proximity Read ↗

The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasmsSemantic proximity Read ↗

Reclassifying myelodysplastic syndromes: what's where in the new WHO and why.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.